nVerses Capital’s Akebia Therapeutics AKBA Stock Holding History

nVerses Capital’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,512	Closed	-$18.5K	–	353
2025 Q4	$18.5K	Buy	+11,512	New	+$24.1K	0.04%	197

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

nVerses Capital's AKBA Position: Q1 2026 in Review

nVerses Capital sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 11,512 shares — an estimated $18.5K sold.

nVerses Capital first reported a position in AKBA in Q4 2025 and held it in 1 quarter. The position peaked at $18.5K in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

nVerses Capital reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
nVerses Capital sold 11,512 Akebia Therapeutics shares in Q1 2026, an estimated $18.5K.
nVerses Capital first reported a position in Akebia Therapeutics in Q4 2025 and held it in 1 quarter.
nVerses Capital's Akebia Therapeutics position peaked at $18.5K in Q4 2025.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on nVerses Capital's 13F filing for Q1 2026, filed 13 May 2026.